EverGlade Consulting

Amendment to BAA Outlines New BARDA Funding Opportunities for Next-generation COVID-19 Vaccines, Monoclonal Antibodies, and Antivirals

by

By Laura Powell, Managing Consultant and Eric Jia-Sobota, Founder CHARLESTON, S.C. , May 19, 2023 /PRNewswire/ — In the latest amendment to its Broad Agency Announcement (BAA), BARDA (Biomedical Advanced Research and Development Authority) is seeking proposals for the development of cost-effective and adaptable therapeutic platforms to treat viral infections, as well as next-generation COVID-19 vaccines. … Read more

EverGlade Consulting Assists Appili Therapeutics in Successful Pursuit of DTRA Funding

by

CHARLESTON, S.C., May 11, 2023 /PRNewswire/ — EverGlade Consulting (“EverGlade”), a national consulting firm, has helped Appili Therapeutics USA Inc. (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, secure an initial contract with the U.S. Air Force Academy (USAFA). USAFA is the prime contractor to DTRA for this program.  The … Read more